Researchers from the Mount Sinai Medical Center, in Miami Beach, concluded in a 2016 review of research that chelation therapy using agents such as ethylenediaminetetraacetic acid (EDTA) can significantly reduce risk of cardiovascular events.

The review highlighted research showing that heavy metals such as cadmium have been linked with increased cardiovascular disease risk, and chelation therapy has been shown to effectively remove heavy metals from the body.

Of particular interest was a study that specifically tested the effectiveness of chelation therapy on reducing cardiovascular events. The randomized, double-blind study involved 1,708 patients ages 50 and up that had experienced a heart attack at least six weeks prior. Half were given 40 infusions of a 500 milliliter chelation solution with EDTA. The other half received a placebo.

Researchers measured deaths, heart attacks and strokes, along with other heart conditions and subsequent hospitalization for an average period of 55 months. They found that the chelation therapy reduced heart attacks and strokes by 23 percent and reduced hospitalization for heart attacks by 28 percent.